Unique ID issued by UMIN | UMIN000024281 |
---|---|
Receipt number | R000027973 |
Scientific Title | Effect of milk protein hydrolysates intake on higher cerebral functions in elderly persons. |
Date of disclosure of the study information | 2016/10/04 |
Last modified on | 2018/04/06 10:12:29 |
Effect of milk protein hydrolysates intake on higher cerebral functions in elderly persons.
Effect of milk protein hydrolysates intake on cerebral functions in elderly persons.
Effect of milk protein hydrolysates intake on higher cerebral functions in elderly persons.
Effect of milk protein hydrolysates intake on cerebral functions in elderly persons.
Japan |
Not applicable
Not applicable | Adult |
Others
NO
To evaluate the efficacy of milk protein hydrolysates intake on higher cerebral functions in elderly persons.
Efficacy
Exploratory
Explanatory
Reaction time of cognitive test
Correct answer ratio of test
Functional MRI
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
NO
YES
Central registration
3
Prevention
Food |
Milk protein hydrolysates (40mg/kg-bw, single dose)
Milk protein (40mg/kg-bw, single dose)
Dietary Fiber (40mg/kg-bw, single dose)
65 | years-old | <= |
Not applicable |
Male and Female
1) Subjects who can receive a MRI examination.
2) Subjects who have no problems in daily life.
1) Subjects with MMSE test score less than 24.
2) Subjects with cognitive impairment by cerebrovascular disease or Alzheimer's disease.
3) Subjects with heart disease.
4) Subjects who had heart attack or cerebral stroke within 6 months.
5) Subjects with acute hepatic dysfunction or active chronic viral hepatitis.
6) Diabetic patients with retinopathy or nephropathy or history of hypoglycemic attack or fasting blood glucose more than 200mg/dl.
7) Subjects with systolic blood pressure more than 180mmHg or diastolic blood pressure more than 110mmHg.
8) Subjects with acute orthopedic pain or neurologic manifestation.
9) Subjects with osteoporosis and history of compression fracture.
10) Subjects with milk allergy.
11) Subjects who regularly use supplements that may influence cerebral function; e.g. DHA, EPA, Catechin.
12) Patients who are judged inappropriate for the study by principal investigator.
60
1st name | |
Middle name | |
Last name | Ken Kimura |
Tokyo Denki University
School of Engineering, Department of Humanities and Social Science
5 Senju-Asahi-cho, Adachi-ku, Tokyo
03-5284-5635
kimura@cck.denki.ac.jp
1st name | |
Middle name | |
Last name | Ken Kimura |
Tokyo Denki University
School of Engineering, Department of Humanities and Social Science
5 Senju-Asahi-cho, Adachi-ku, Tokyo
03-5284-5635
kimura@cck.denki.ac.jp
Tokyo Denki University
Morinaga Milk Industry Co., LTD.
Profit organization
NO
2016 | Year | 10 | Month | 04 | Day |
Unpublished
Completed
2016 | Year | 09 | Month | 28 | Day |
2016 | Year | 10 | Month | 04 | Day |
2018 | Year | 03 | Month | 31 | Day |
2018 | Year | 04 | Month | 05 | Day |
2016 | Year | 10 | Month | 04 | Day |
2018 | Year | 04 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027973
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |